KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Notes Payables (2020 - 2024)

Recursion Pharmaceuticals (RXRX) has disclosed Notes Payables for 5 consecutive years, with $55000.0 as the latest value for Q1 2024.

  • For the quarter ending Q1 2024, Notes Payables fell 91.68% year-over-year to $55000.0, compared with a TTM value of $55000.0 through Mar 2024, down 91.68%, and an annual FY2023 reading of $41000.0, down 57.73% over the prior year.
  • Notes Payables was $55000.0 for Q1 2024 at Recursion Pharmaceuticals, up from $41000.0 in the prior quarter.
  • Across five years, Notes Payables topped out at $3.1 million in Q2 2021 and bottomed at $41000.0 in Q4 2023.
  • Average Notes Payables over 5 years is $645428.6, with a median of $96000.0 recorded in 2022.
  • The sharpest move saw Notes Payables plummeted 97.03% in 2022, then surged 631.58% in 2023.
  • Year by year, Notes Payables stood at $1.1 million in 2020, then crashed by 91.61% to $90000.0 in 2021, then rose by 7.78% to $97000.0 in 2022, then crashed by 57.73% to $41000.0 in 2023, then surged by 34.15% to $55000.0 in 2024.
  • Business Quant data shows Notes Payables for RXRX at $55000.0 in Q1 2024, $41000.0 in Q4 2023, and $695000.0 in Q3 2023.